Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.45 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085617 | 0.89 | STAT6 (0.45) | MAPTGSK3BMAPK1STAT6GSK3A | |
| SCHEMBL6085442 | 0.87 | MAPT (0.43) | MAPTGSK3BGAAL3MBTL1SMN1; SMN2 | |
| SCHEMBL5089374 | 0.84 | GSK3B (0.42) | MAPTGSK3BL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL5100090 | 0.84 | GSK3B (0.42) | MAPTGSK3BSMN1; SMN2MAPK1GSK3A | |
| SCHEMBL5099914 | 0.80 | BRD4 (0.44) | MAPTGAAL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL5093484 | 0.79 | ALDH1A1 (0.47) | MAPTGSK3BGAAL3MBTL1KDM4E | |
| SCHEMBL5100370 | 0.77 | GSK3B (0.65) | MAPTGSK3BGAAL3MBTL1TDP1 | |
| SCHEMBL5091616 | 0.76 | ALDH1A1 (0.40) | MAPTL3MBTL1SMN1; SMN2TDP1MAPK1 | |
| SCHEMBL7198334 | 0.76 | MEN1 (0.46) | MAPTGSK3BGAASTAT6MEN1 | |
| SCHEMBL5100135 | 0.75 | GSK3B (0.42) | MAPTGSK3BMAPK1GSK3ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| EP-1087963-B1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | MAPT 134/4885GSK3B 1/4885GAA 954/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | MAPT 146/4885GSK3B 1/4885GAA 937/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | MAPT 146/4885GSK3B 1/4885GAA 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.